Could a Two-Drug HIV pill work for transgender women?

NCT ID NCT06967753

Recruiting now Disease control Sponsor: UBATEC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing whether switching to a two-drug HIV pill (dolutegravir plus lamivudine) can keep the virus under control in transgender women who are already on a stable three-drug regimen. About 50 participants will take the new pill once daily for 48 weeks. The main goal is to see if the virus stays suppressed, with a focus on safety and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dolutegravir and lamivudine (two-drug HIV pill)
What this could lead to: If successful, this could show that a simpler two-drug regimen works well for transgender women with HIV, potentially reducing side effects and pill burden.
What could go wrong: This is a small, early-phase study with only 50 participants and no comparison group, so results may not apply to everyone. There is a risk the simpler regimen may not keep the virus fully suppressed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV HIV-1

Contacts and locations

Locations

Hospital General de Agudos Dr. Juan A. Fernández, Infectious Diseases Division
RECRUITING

Buenos Aires, Buenos Aires F.D., 1425, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.